A healthy lifestyle attenuates the effect of polypharmacy on total and cardiovascular mortality: a national prospective cohort study

David Martinez-Gomez1,3, Pilar Guallar-Castillon2,3, Sara Higueras-Fresnillo1, Jose R. Banegas2, Kabir P. Sadarangani4,5 & Fernando Rodriguez-Artalejo2,3

This work examines whether the increased all-cause and cardiovascular disease (CVD) mortality associated with polypharmacy could be offset by a healthy lifestyle. We included a prospective cohort of 3,925 individuals representative of the Spanish population aged ≥60 years, who were recruited in 2000–2001 and followed up through 2014. Polypharmacy was defined as treatment with ≥5 medications. The following lifestyle behaviors were considered healthy: not smoking, eating a healthy diet, being physically active, moderate alcohol consumption, low sitting time, and adequate sleep duration. Individuals were classified into three lifestyle categories: unfavorable (0–2), intermediate (3–4) favorable (5–6). Over a median 13.8-y follow-up, 1,822 all-cause and 675 CVD deaths occurred. Among individuals with polypharmacy, intermediate and favorable lifestyles were associated with an all-cause mortality reduction (95% confidence interval [CI]) of 47% (34–58%) and 54% (37–66%), respectively; 37% (9–56%) and 60% (33–76%) for CVD death, respectively. The theoretical adjusted hazard ratio (95%CI) associated with replacing 1 medication with 1 healthy lifestyle behavior was 0.73 (0.66–0.81) for all-cause death and 0.69 (0.59–0.82) for CVD death. The theoretical adjusted hazard ratio (95%CI) for all-cause and CVD mortality associated with simply reducing 1 medication was 0.88 (0.83–0.94) and 0.83 (0.76–0.91), respectively. Hence, adherence to a healthy lifestyle behavior can reduce mortality risk associated with polypharmacy in older adults.

Improvements in the effectiveness and coverage of health care, including pharmacological treatments, have substantially contributed to recent gains in health expectancy in old age in high-income countries1. However, prevention and management of age-related chronic conditions have resulted in an increased number of medications taken by older adults2,3. Polypharmacy, defined as the use of multiple medications or the administration of an excessive number of medications4, is very frequent in the elderly and has been associated with many adverse health outcomes, including poor treatment adherence, adverse drug reactions, drug-drug interactions, drug-disease interactions, falls, fractures, frailty, hospitalizations, physical and cognitive functional impairments, and medical errors which, in turn, increase the risk of death5. In addition, costs of drug treatments have risen sharply in recent decades, and represent a challenge for healthcare systems sustainability6,7. Unfortunately, there is little high-quality evidence to date on how to reduce polypharmacy, with deprescribing being the main strategy8–10.

A healthy lifestyle has been shown to improve health in older adults11,12. Several healthy lifestyle behaviors, including not smoking, a healthy diet, being physically active, moderate alcohol consumption, less sedentariness and adequate sleep duration have well-documented positive effects on mortality in the elderly; in fact, it seems that it is never too late to obtain some benefits from adopting healthy lifestyle behaviors13–18. Therefore, it is of interest to assess whether the adverse mortality effect of polypharmacy could be attenuated by a healthy lifestyle.
in the old age. These findings might represent an important shift in the approach to provide health in among older adults because the objectives go beyond preventing deaths exclusively through pharmacology treatments. Hence, we used data from a cohort of older adults in Spain to examine whether the increased all-cause and cardiovascular disease (CVD) mortality associated with polypharmacy could be offset by a healthy lifestyle. Additionally, we assessed the theoretical mortality benefits that could be obtained by replacing medications with healthy lifestyle behaviors in individuals with polypharmacy.

Methods

Study design and participants. We analyzed data from a cohort of 4,008 individuals, representative of the non-institutionalized population aged ≥60 years in Spain. The study participants were recruited in 2000/2001 using probabilistic and multistage cluster sampling. The clusters were initially stratified according to region of residence and size of municipality. Next, census sections and households were successively chosen randomly within each cluster. Study participants were finally selected in sex and age strata. The final study participation rate was 71%. Data were collected by home-based personal interview and physical examination, performed by trained personnel. All methods were carried out in accordance with relevant guidelines/regulations. The study was approved by the Clinical Research Ethics Committee of the La Paz University Hospital in Madrid, Spain. All participants provided written informed consent.

Exposure variables. During the home visit, participants were asked to show all prescribed and over-the-counter medications that they were currently taking. We recorded up to ten medications, and the total number of drugs was classified into three categories: 0–1 medications, 2–4 medications and ≥5 medications or polypharmacy in the current study.

We considered six lifestyle behaviors that were self-reported with standardized and validated questionnaires: (i) smoking, (ii) diet, (iii) alcohol consumption, (iv) physical activity, (v) sedentary behavior and (vi) sleep duration. According to published evidence and lifestyle recommendations, the following lifestyle behaviors were considered healthy: not smoking (never smoking or having quit >15 years ago), eating a healthy diet (index ≥median in the cohort), being physically active (very/moderately active), moderate alcohol intake (≤20 and ≤30 g/d in female and male drinkers, respectively), low sedentariness (≤7 h/d), and adequate sleep duration (7–8 h/d). A healthy lifestyle score was defined as the number of healthy lifestyle behaviors, and individuals were classified into three categories: unfavorable (0–2 healthy lifestyle behaviors), intermediate (3–4 healthy lifestyle behaviors), and favorable (5–6 healthy lifestyle behaviors).

Ascertaining of mortality. The outcome variables were all-cause and CVD mortality from the study baseline through the end of follow-up at December 31, 2014. The number, cause and date of deaths were obtained by a computerized search of the National Death Index of the Ministry of Health and the vital registry of the National Institute for Statistics. The vital status was successfully ascertained for 99.9% of the cohort. The underlying cause of death was determined by a nosologist according to the International Classification of Diseases, Tenth Edition, with cardiovascular death corresponding to codes 100-199.

Other variables. Sex, age, and educational level were recorded. Body weight, height and waist circumference were measured and body mass index (BMI) was calculated as kg/m². Blood pressure readings were performed in the right arm at the level of the heart using standardized methods. Hypercholesterolemia was defined as an affirmative answer to the following question: Has your doctor ever told you that you have high (blood) cholesterol? Cognitive function was assessed with the Mini-Mental State Examination. Agility and mobility limitations were defined as an affirmative answer to standardized questions. Finally, we registered the following diseases diagnosed by a physician and reported by the study participant: chronic lung disease, CVD, diabetes mellitus, cancer at any site, and depression.

Statistical analyses. Of the 4,008 study participants, 83 were excluded because of missing data on lifestyle behaviors or other variables, so the final sample comprised 3,925 individuals (2,214 women). Pearson correlation was used to analyze the relationship between the number of medications and healthy lifestyle behaviors.

Cumulative all-cause and CVD mortality according to medication and healthy lifestyle behaviors were calculated using the Kaplan-Meier method, and differences were assessed with log-rank tests. We also used Cox proportional hazards regression, with days as the time scale, to estimate the hazard ratios (HRs) and 95% confidence intervals (CIs) for all-cause and CVD mortality associated with medication or healthy lifestyle behaviors. The analyses took 0–1 medications or a favorable lifestyle, respectively, as the reference category. The dose-response relationship was tested with a P for trend, calculated by modeling the number of medications and healthy lifestyle behaviors as continuous variables; we also used restricted cubic spline regression to graphically illustrate this relationship.

Next, to examine whether healthy lifestyle behaviors attenuate the effect of medications on all-cause or CVD mortality we initially estimated the association between healthy lifestyle behaviors and mortality outcomes stratified by medication categories. Also, we checked the potential modifier effect of medications on the associations between healthy lifestyle behaviors and mortality outcomes by including an interaction term in Cox models. Then, we assessed the association of the combined exposure to healthy lifestyle behaviors and medications with mortality by modelling nine categories of exposure (that is, 3 medication categories × 3 healthy lifestyle behaviors categories) and participants taking 0–1 medications with a favorable lifestyle was the reference category – hypothetically the healthiest category.

Finally, the theoretical all-cause and CVD mortality benefit from reduced polypharmacy, achieved by replacing 1 medication with 1 healthy lifestyle behavior, was estimated in a way similar to isothermal/isocaloric substitution models among participants taking ≥5 medications. Since these methods of analysis assume a constant
amount of "discretionary time or calories", we considered that the total number of medications and healthy lifestyle behaviors represented a constant amount of "discretionary options". The theoretical mortality benefits of deprescribing 1 medication to reduce polypharmacy was operationalized as decreasing any medication and tested by reversing the order in the medication exposure variable (i.e., decreasing the number of medications taken) among older adults taking ≥5 medications. We also calculated a risk advancement period, which shows the difference in survival in persons with a varying number of medications or healthy lifestyle behaviors that is equivalent to the all-cause or CVD mortality associated with each 1-year increase in chronological age.3

Analyses were first adjusted for sex and age (model 1), and subsequently for educational attainment, BMI, waist circumference, systolic blood pressure, hypercholesterolemia, Mini-Mental State Examination score, agility limitation, mobility limitation, chronic lung disease, CVD, cancer, diabetes mellitus, and depression (model 2). These covariates were selected according to previous works in the same research area.5 Multicollinearity detection was examined in all analyses, but variance inflation factors were in the normal range.

We assessed the assumption of proportionality of hazards both graphically and by testing the significance of the interaction of medication or healthy lifestyle with time of follow-up, and we found no evidence of departure from such assumption (all P for interaction > 0.1). Statistical significance was set at two-sided P < 0.05. Analyses were performed with STATA® v.14.1 for Macintosh.

Results

Descriptive characteristics of the study participants at baseline by medication and healthy lifestyle categories are reported in Table 1. Overall, compared to participants with 0–1 medications or with a favorable lifestyle, those taking ≥5 medications or with an unfavorable lifestyle were older and more frequently women, and had lower education, more functional and cognitive limitations, and more chronic diseases. There was only a weak correlation between the number of medications and healthy lifestyle behaviors (r = −0.15, P < 0.001).

Over a median follow-up of 13.8 years (5th to 95th percentile: 1.9–14.2) a total of 1,822 deaths occurred, 675 of them due to cardiovascular disease. In Kaplan–Meier analyses, cumulative all-cause and CVD deaths progressively increased with the number of medications and decreased from unfavorable through favorable categories of lifestyle (all log–rank tests P < 0.001) (Figure S1).

After multivariable adjustment (model 2, Table 2), and compared to taking 0–1 medications, the adjusted HR (95%CI) of all-cause death was 1.32 (1.15–1.51) for 3–4 medications and 1.75 (1.49–2.06) for ≥5 medications; corresponding results for CVD mortality were 1.50 (1.17–1.92) and 2.11 (1.60–2.78). In contrast, those with intermediate and favorable vs unfavorable lifestyle had an adjusted HR (95%CI) of 0.58 (0.51–0.67) and 0.48 (0.40–0.57) for all-cause mortality, and of 0.55 (0.43–0.70) and 0.45 (0.32–0.59) for CVD mortality (Table 2). Both medications and healthy lifestyles showed a clear dose–response with mortality (Figure S2); the adjusted HR (95%CI) for all-cause and CVD mortality associated with 1-medication increase were 1.12 (1.09–1.14) and 1.15 (1.10–1.19), respectively, and with 1-healthy lifestyle behavior increase were 0.81 (0.77–0.85) and 0.78 (0.72–0.85), respectively (all P for trend < 0.001) (Table 2). These associations remained virtually the same after adjustment for the other exposure variable (Table S1).

Table 1. Characteristics of the participants at baseline, by categories of medication and healthy lifestyle. Values are means ± SD or %. MMSE: Mini-Mental State examination.
The association between healthy lifestyle behaviors and mortality did not vary by medication category (all $P$ for interactions $>0.1$). Among participants with polypharmacy ($\geq 5$ medications), an intermediate or favorable lifestyle was associated with an all-cause mortality reduction (95%CI) of 47% (34–58%) and 54% (37–66%), respectively; for CVD death, figures were 37% (9–56%) and 60% (33–76%) (Table 3). In combined analyses, adherence to a healthier lifestyle attenuated the increased all-cause and CVD mortality associated with taking 2–4 medications and polypharmacy remarkably (Fig. 1 and Table S2). Also, as compared to participants with 0–1 medications and a favorable lifestyle, those with $\geq 5$ medications and an unfavorable lifestyle had the highest risk of all-cause death ($HR = 3.70, 95\%CI: 2.67–5.12$) and CVD death ($HR = 5.09, 95\%CI: 2.84–9.10$) (Fig. 1).

### Table 2. All-cause and cardiovascular disease (CVD) mortality risk according to number of medications and healthy lifestyle behaviors in older adults. Model 1 adjusted for sex and age. Model 2 adjusted as in model 1 and for educational attainment, body mass index, waist circumference, systolic blood pressure, hypercholesterolemia, Mini-Mental State Examination, agility limitations, mobility limitations, chronic lung disease, CVD, cancer, diabetes mellitus, and depression.

| Medication category | $n$ | All-cause mortality HR (95%CI) | CVD mortality HR (95%CI) |
|--------------------|-----|-------------------------------|--------------------------|
|                    | Cases | Model 1 | Model 2 | Cases | Model 1 | Model 2 | Cases | Model 1 | Model 2 | Cases | Model 1 | Model 2 |
| 0–1 medications    | 1295  | 452    | 1 (Reference) | 1 (Reference) | 137  | 1 (Reference) | 1 (Reference) |
| 2–4 medications    | 1787  | 842    | 1.38 (1.20–1.57) | 1.32 (1.15–1.51) | 316  | 1.64 (1.29–2.08) | 1.50 (1.17–1.92) |
| $\geq 5$ medications | 843  | 528    | 2.03 (1.75–2.34) | 1.75 (1.49–2.06) | 222  | 2.68 (2.09–3.43) | 2.11 (1.60–2.78) |
| $P$ for trend       |        |        | <0.001             | <0.001             |        | <0.001             | <0.001             |
| Per 1-medication increase |  | 1.14 (1.11–1.16) | 1.12 (1.09–1.14) | 1.19 (1.15–1.23) | 1.15 (1.10–1.19) |

### Table 3. All-cause and cardiovascular disease (CVD) mortality risk according to healthy lifestyle in older adults stratified by medication category in older adults. Model 1 adjusted for sex and age. Model 2 adjusted as in model 1 and for educational attainment, body mass index, waist circumference, systolic blood pressure, hypercholesterolemia, Mini-Mental State Examination, agility limitations, mobility limitations, chronic lung disease, CVD, cancer, diabetes mellitus, and depression.

| Healthy lifestyle category | $n$ | All-cause mortality HR (95%CI) | CVD mortality HR (95%CI) |
|---------------------------|-----|-------------------------------|--------------------------|
|                           | Cases | Model 1 | Model 2 | Cases | Model 1 | Model 2 | Cases | Model 1 | Model 2 | Cases | Model 1 | Model 2 |
| With 0–1 medications      |       |        |        |        |        |        |        |        |        |        |        |        |
| Unfavorable lifestyle     | 147  | 93    | 1 (Reference) | 1 (Reference) | 43   | 1 (Reference) | 1 (Reference) |
| Intermediate lifestyle    | 594  | 267    | 0.63 (0.45–0.89) | 0.65 (0.45–0.88) | 72   | 0.41 (0.25–0.67) | 0.42 (0.26–0.70) |
| Favorable lifestyle       | 354  | 92    | 0.55 (0.37–0.80) | 0.56 (0.38–0.83) | 22   | 0.34 (0.18–0.63) | 0.39 (0.20–0.74) |
| $P$ for trend             | <0.001 |        | <0.001             | <0.001             | <0.001             | <0.001             |
| Per 1-healthy lifestyle increase |  | 0.85 (0.76–0.94) | 0.85 (0.76–0.95) | 0.71 (0.59–0.86) | 0.73 (0.60–0.89) |

| With 2–4 medications      |       |        |        |        |        |        |        |        |        |        |        |        |
| Unfavorable lifestyle     | 304  | 207    | 1 (Reference) | 1 (Reference) | 81   | 1 (Reference) | 1 (Reference) |
| Intermediate lifestyle    | 1031 | 478    | 0.59 (0.49–0.71) | 0.62 (0.51–0.75) | 175  | 0.57 (0.39–0.82) | 0.57 (0.40–0.83) |
| Favorable lifestyle       | 452  | 157    | 0.43 (0.34–0.54) | 0.45 (0.35–0.58) | 60   | 0.46 (0.29–0.74) | 0.47 (0.30–0.75) |
| $P$ for trend             | <0.001 |        | <0.001             | <0.001             | <0.001             | <0.001             |
| Per 1-healthy lifestyle increase |  | 0.78 (0.73–0.83) | 0.79 (0.74–0.85) | 0.77 (0.68–0.86) | 0.78 (0.69–0.88) |

| With $\geq 5$ medications |       |        |        |        |        |        |        |        |        |        |        |        |
| Unfavorable lifestyle     | 214  | 159    | 1 (Reference) | 1 (Reference) | 71   | 1 (Reference) | 1 (Reference) |
| Intermediate lifestyle    | 483  | 282    | 0.52 (0.41–0.64) | 0.53 (0.42–0.66) | 127  | 0.57 (0.41–0.80) | 0.63 (0.44–0.91) |
| Favorable lifestyle       | 146  | 77     | 0.46 (0.35–0.61) | 0.46 (0.34–0.63) | 24   | 0.36 (0.22–0.57) | 0.40 (0.24–0.67) |
| $P$ for trend             | <0.001 |        | <0.001             | <0.001             | <0.001             | 0.002             |
| Per 1-healthy lifestyle increase |  | 0.80 (0.74–0.87) | 0.80 (0.74–0.87) | 0.78 (0.69–0.88) | 0.81 (0.70–0.92) |
Among those with polypharmacy, the adjusted mortality HR (95%CI) associated with replacing 1 medication with 1 healthy lifestyle behavior was 0.73 (0.66–0.81) for all-cause death and 0.69 (0.59–0.82) for CVD death (Figure S3); it is approximately equivalent to the reduced mortality associated with being 3 years younger. This suggests that replacement might have greater benefits than deprescribing, because the adjusted HR (95%CI) for all-cause and CVD mortality associated with simply reducing 1 medication was 0.88 (0.83–0.94) and 0.83 (0.76–0.91), respectively (both \( P \) for trend < 0.001); this is a mortality equivalent to a 1–1.5 years younger age.

Discussion
In a population-based cohort of older adults in Spain, adherence to a healthier lifestyle was linked to a reduction of all-cause and CVD mortality associated with polypharmacy. Specifically, among individuals with polypharmacy, those with a favorable lifestyle showed a 54% and 60% lower all-cause and CVD death risk, respectively, than those with an unfavorable lifestyle. In addition, the theoretical effect of replacing medications with healthy lifestyle behaviors evinced a greater reduction of mortality than simply deprescribing the number of medications. Since taking medications and adherence to a healthy lifestyle are not related in the old age, these findings are especially important for older adults, which usually take an excessive number of medications, and therefore, public health and clinical strategies are needed to improve their health behaviors.

Although many clinical trials have shown that drug treatments improve survival in different clinical scenarios, we found that the number of medications taken had a direct dose-response relationship with mortality from all causes and CVD—the leading cause of death among older adults. Individuals with \( \geq 5 \) medications had about two times higher risk of death (HR = 1.75, 95%CI: 1.49–2.06 for all-cause mortality and HR = 2.11, 95%CI: 1.60–2.78 for CVD mortality) than those with none or only 1 medication. Our results are in line with most previous research on this topic, regardless of the cut-point selected to define polypharmacy. In fact, studies with better adjustment for the confounding effect of morbidity found a clearer association between the number of medications taken and mortality. Polypharmacy, therefore, can be considered a “red flag” for high mortality risk in older adults. Consequently, the increased risks of overtreatment by too much medication is a public health message that should be disseminated throughout society, given the widespread tendency to self-administer over-the-counter medications.

In our study, adherence to a healthier lifestyle partially offsets the increased mortality associated with polypharmacy. Interestingly, even an intermediate lifestyle (i.e., 3–4 out of 6 healthy lifestyle behaviors) showed a significant reduction in the increased mortality; this, and the observed dose-response reduction of mortality with a higher number of healthy lifestyle behaviors, indicates that each of them “counts” for a certain benefit. In fact, older adults with polypharmacy who adhered to a favorable lifestyle had an excess mortality which was similar
or even lower to that of those with 0–1 medications and an unfavorable lifestyle for all-cause and CVD mortality, respectively (Fig. 1).

On the other hand, participants taking 2–4 medications also had an increased all-cause (HR = 1.32, 95%CI: 1.15–1.51) and CVD (HR = 1.50, 95%CI: 1.17–1.92) mortality risk in our cohort. These older adults, especially those who take 4 medications, are at risk for polypharmacy, and to avoid its initiation, adherence to healthier lifestyles would be essential and is supported by our results. For example, among individuals taking 2–4 medications, those with a favorable lifestyle had a 55% and 53% lower all-cause and CVD death risk, respectively, than did those with an unfavorable lifestyle (Table 3); they even had a lower mortality risk than those taking none or 1 medication and adherence to an unfavorable lifestyle (Fig. 1).

Deprescribing is the process of tapering, stopping, discontinuing, or withdrawing medications, supervised by a healthcare professional (e.g., general physicians, nurses, pharmacists), with the goal of reducing polypharmacy. Although it is feasible and safe, two recent meta-analyses on the effect of deprescribing found no convincing evidence of benefits in mortality. Page et al. reported that, in nonrandomized studies, deprescribing to reduce polypharmacy significantly decreased all-cause mortality (OR = 0.32, 95%CI: 0.17–0.60), but this was not statistically significant in randomized trials (OR = 0.82, 95%CI 0.61–1.11). Moreover, Johansson et al. found that deprescribing polypharmacy had no effect on all-cause mortality (OR = 1.02, 95%CI: 0.84–1.23). Both reviews also indicated that the quality of the evidence was low and that more effective strategies to reduce polypharmacy should be developed and assessed. In our study, we examined the impact of replacing medications with healthy lifestyle behaviors; thus, this included the joint effect of “deprescribing drug treatments” and “prescribing a healthy lifestyle” as compared with only deprescribing. While we acknowledge that the effect of medical advice on adopting healthy lifestyle behaviors in healthcare settings could be modest, our results suggest that the benefit of replacement could be 2 to 3 times higher than that of deprescribing; for example, while replacing 1 medication with 1 healthy lifestyle behavior was linked to a 27% reduction of all-cause mortality, reducing 1 medication was associated with only a 12% reduction. Thus a healthy lifestyle is “medicine” and may replace other medications. However, it must be noted that these findings are theoretical because when deprescribing some considerations such as harmful effects, the stage of the disease, doses, the importance of this medication at short- medium- and long-term, and individual barriers, could not be taken into account in our study.

This study has several strengths, including a large representative sample of community-dwelling older adults that allows for certain generalization of results. Also, study variables were collected by trained staff using standardized methods. Moreover, analyses were adjusted for a substantial number of confounders, including chronic morbidity. Despite these strengths, our findings should be interpreted in the context of the following methodological limitations. First, since this is an observational study, there might be some residual confounding, and associations may not imply causation. However, the strength and dose-response of the associations found, the consistency across medication categories, and a long follow-up - which makes reverse causality less likely - all lend credence to our study results and support causal inference. Second, information on drug treatments and lifestyle behaviors was obtained at baseline. Our analyses assumed that medication exposure and lifestyle behaviors have certain stability over time, but some changes are still possible and would likely shift the observed associations toward the null. Third, lifestyle behaviors were self-reported and dichotomized, which may have led to recall bias and non-differential misclassification; again, this could have underestimated the impact of polypharmacy and lifestyle on mortality. Fourth, although the analyses were adjusted for several confounding variables, some potential confounders were not included due to they were not available in our study (e.g., dietary patterns, family health history, blood samples). In addition, we calculated a propensity score in post hoc analyses with our 12 covariates, which have been suggested as a potential confounder in pharmacoepidemiology, and the associations between polypharmacy and mortality did no change.

In conclusion, adherence to a healthy lifestyle may help to reduce the increased risk of all-cause and CVD death associated with polypharmacy in older adults. In addition, replacing medications with healthy lifestyle behaviors may be theoretically a useful strategy to reduce polypharmacy and maximize health benefits, as compared to only deprescribing. However, this strategy should be directly tested in clinical trials which, in addition to mortality, focus on other outcomes relevant for older people, such as frailty, falls, and cognitive and physical decline.

References
1. Mathers, C. D., Stevens, G. A., Boerma, T., White, R. A. & Tobias, M. I. Causes of international increases in older age life expectancy. Lancet. 385, 540–548 (2015).
2. Marengoni, A. et al. Aging with multimorbidity: a systematic review of the literature. Ageing Res Rev. 10, 430–439 (2011).
3. Marengoni, A. & Onder, G. Guidelines, polypharmacy, and drug-drug interactions in patients with multimorbidity. BMJ. 350, h1059 (2015).
4. World Health Organization. A Glossary of Terms for Community Health Care and Services for Older Persons. (World Health Organization, 2014).
5. Fried, T. R. et al. Health outcomes associated with polypharmacy in community-dwelling older adults: a systematic review. J Am Geriatr Soc. 62, 2261–2272 (2014).
6. Bloom, D. E. et al. Macroeconomic implications of population ageing and selected policy responses. Lancet. 385, 649–657 (2015).
7. Cahir, C. et al. Potentially inappropriate prescribing and cost outcomes for older people: a national population study. Br J Clin Pharmacol. 69, 543–552 (2010).
8. Page, A. T., Clifford, R. M., Putter, K., Schwartz, D. & Etherton-Beer, C. D. The feasibility and effect of deprescribing in older adults on mortality and health: a systematic review and meta-analysis. Br J Clin Pharmacol. 82, 583–623 (2016).
9. Johansson, T. et al. Impact of strategies to reduce polypharmacy on clinically relevant endpoints: a systematic review and meta-analysis. Br J Clin Pharmacol. 82, 532–548 (2016).
10. Reeve, E., Thompson, W. & Farrell, B. Deprescribing: A narrative review of the evidence and practical recommendations for recognizing opportunities and taking action. Eur J Intern Med. 38, 3–11 (2017).
11. World Health Organization. The World report on ageing and health. (World Health Organization, 2015).
12. Anton, S. D. et al. Successful aging: Advancing the science of physical independence in older adults. Ageing Res Rev. 24, 304–327 (2015).
13. Loef, M. & Walach, H. The combined effects of healthy lifestyle behaviors on all-cause mortality: a systematic review and meta-analysis. Prev Med. 55, 163–170 (2012).
14. Knoops, K. T. et al. Mediterranean diet, lifestyle factors, and 10-year mortality in elderly European men and women: the HALE project. JAMA. 292, 1433–1439 (2004).
15. Rizzuto, D., Orsini, N., Qiu, C., Wang, H. X. & Fratiglioni, L. Lifestyle, social factors, and survival after age 75: population based study. BMJ. 345, e5568 (2012).
16. Martínez-Gómez, D., Guallar-Castillón, P., León-Muñoz, L. M., López-Garcia, E. & Rodríguez-Artalejo, F. Combined impact of traditional and non-traditional health behaviors on mortality: a national prospective cohort study in Spanish older adults. BMC Med. 11, 4 (2013).
17. Ding, D., Rogers, K., van der Ploeg, H., Stamatakis, E. & Bauman, A. E. Traditional and Emerging Lifestyle Risk Behaviors and All-Cause Mortality in Middle-Aged and Older Adults: Evidence from a Large Population-Based Australian cohort. PLoS Med. 12, e1001917 (2015).
18. Hamer, M., Bates, C. J. & Mishra, G. D. Multiple health behaviors and mortality risk in older adults. J Am Geriatr Soc. 59, 370–372 (2011).
19. Gutiérrez-Fiscas, I. L., López, E., Banegas, J. R., Graciani, A. & Rodríguez-Artalejo, F. Prevalence of overweight and obesity in elderly people in Spain. Obes Res. 12, 710–715 (2004).
20. Gnijdic, D. et al. Polypharmacy cutoff and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes. J Clin Epidemiol. 65, 989–995 (2012).
21. Pérez-Tasigchana, R. F. et al. Mediterranean Diet and Health-Related Quality of Life in Two Cohorts of Community-Dwelling Older Adults. PLoS One. 11, e0151596 (2016).
22. Guallar-Castillón, P. et al. Consumption of alcoholic beverages and subjective health in Spain. J Epidemiol Community Health. 55, 648–652 (2001).
23. Martínez-Gómez, D., Guallar-Castillón, P., Mota, J., Lopez-Garcia, E. & Rodriguez-Artalejo, F. Physical Activity, Sitting Time and Mortality in Older Adults with Diabetes. Int J Sports Med. 36, 1206–1211 (2015).
24. León-Muñoz, L. M. et al. Continued sedentariness, change in sitting time, and mortality in older adults. Med Sci Sports Exerc. 45, 1501–1507 (2013).
25. Martínez-Gómez, D., Guallar-Castillón, P. & Rodríguez-Artalejo, F. Sitting Time and Mortality in Older Adults With Disability: A National Cohort Study. J Am Med Dir Assoc. 17, 960.e15–20 (2016).
26. Mesas, A. E., López-Garcia, E., León-Muñoz, L. M., Guallar-Castillón, P. & Rodríguez-Artalejo, F. Sleep duration and mortality according to health status in older adults. J Am Geriatr Soc. 58, 1870–1877 (2010).
27. Banegas, J. R. et al. Hypertension magnitude and management in the elderly population of Spain. J Hypertens. 20, 2157–2164 (2002).
28. Folstein, M. F., Folstein, S. E. & McHugh, P. R. Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 12, 189–198 (1975).
29. Lobo, A. et al. Revalidation and standardization of the cognition mini-exam (first Spanish version of the Mini-Mental Status Examination) in the general geriatric population. Med Clin (Barc). 112, 767–774 (1999).
30. Graciani, A., Banegas, J. R., López-García, E. & Rodríguez-Artalejo, F. Prevalence of disability and associated social and health-related factors among the elderly in Spain: a population-based study. Maturitas. 48, 381–392 (2004).
31. Mekary, R. A., Willett, W. C., Hu, F. B. & Ding, E. L. Isotemporal substitution paradigm for physical activity epidemiology and weight change. Am J Epidemiol. 170, 519–527 (2009).
32. Song, M. et al. Association of Animal and Plant Protein Intake With All-Cause and Cause-Specific Mortality. JAMA Intern Med. 176, 1453–1463 (2016).
33. Godlee, F. Less medicine is more. BMJ. 338, b2561 (2009).
34. Malhotra, A. et al. Choosing Wisely in the UK: the Academy of Medical Royal Colleges’ initiative to reduce the harms of too much medicine. BMJ. 350, h2308 (2015).
35. Scott, I. A. et al. Reducing inappropriate polypharmacy: the process of deprescribing. JAMA Intern Med. 175, 827–834 (2015).
36. Qato, D. M., Wilder, J., Schumm, L. P., Gillet, V. & Alexander, G. C. Changes in prescription and Over-the-Counter Medication and Dietary Supplement Use Among Older Adults in the United States, 2005 vs 2011. JAMA Intern Med. 176, 473–482 (2016).
37. Curry, S. J., Grossman, D. C., Whitlock, E. P. & Cantu, A. Behavioral counseling research and evidence-based practice recommendations: U.S. Preventive Services Task Force perspectives. Ann Intern Med. 160, 407–413 (2014).
38. Lin, J. S. et al. Behavioral counseling to promote a healthy lifestyle in persons with cardiovascular risk factors: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 161, 568–578 (2014).
39. Schöttker, B. et al. Polypharmacy and mortality: new insights from a large cohort of older adults by detection of effect modification by multi-morbidity and comprehensive correction of confounding by indication. Eur J Clin Pharmacol. 73, 1041–1048 (2017).

Acknowledgements
This work was supported by FIS grants 16/609 and 13/0288 (Instituto de Salud Carlos III, State Secretary of R + D + I and FEDER/FSE), MICINCYT R + D + I grant (DEP2013-47786-R), the FRAILOMIC Initiative (European Union FP7-HEALTH-2012-Proposal No. 305483-2), and the ATHLOS project (European project H2020- Project ID:635316).

Author Contributions
D.M.G. and F.R.A. developed the hypothesis and study design. D.M.G. did the statistical analysis. P.G.C., J.R.B., and F.R.A. obtained funding for the U.A.M. study. D.M.G. and F.R.A. had full access to the data and take responsibility for the integrity of the data and the accuracy of the data analysis. All authors were involved in further analysis and interpretation of data, drafting the manuscript, and critical revision of the manuscript for important intellectual content. D.M.G. is the guarantor.

Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-018-30840-9.

Competing Interests: The authors declare no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
